Why the study?
Does the assessment and management of non-HDL cholesterol improve cardiovascular risk stratification compared to focusing mainly on LDL cholesterol in patients with dyslipidemia?
Does the assessment and management of non-HDL cholesterol improve cardiovascular risk stratification compared to focusing mainly on LDL cholesterol in patients with dyslipidemia?
This review highlights that non-HDL cholesterol is a crucial, yet underrecognized and undertreated, marker of cardiovascular risk in dyslipidemia management.
May warrant attention to non-HDL in dyslipidemia risk assessment; leaves open whether it improves stratification over LDL-focused strategies.
Dyslipidaemia is a major contributor to cardiovascular disease which has assumed epidemic proportions worldwide. The traditional approach to the management of dyslipidaemia focusses mainly on LDL cholesterol. However, recent evidence suggests that non HDL-C is an important marker of cardiovascular risk and might play a more important role than LDL cholesterol in the causation of cardiovascular disease. Non HDL cholesterol includes all ApoB containing lipoproteins and can be tested more reliably and conveniently with the available laboratory assays. Inspite of the evidence, the role of non HDL cholesterol in atherosclerosis is underrecognised and this lipid parameter is often undertreated. This review highlights the importance of non HDL cholesterol in dyslipidaemia management, both in diabetics and otherwise.
No takes yet. Share an insight, caveat, or question.
Chowdhury et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: